| abstract |
Disclosed are antagonists of the human proprotein convertase subtilisin kexin 9 ("PCSK9"). The disclosed antagonists are effective in inhibiting PCSK9 function and thus present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The invention also discloses nucleic acids encoding the antagonists, vectors, host cells and compositions comprising the antagonists. Also disclosed are methods of producing PCSK9-specific antagonists, as well as methods of using the antagonists to inhibit or antagonize PCSK9 function, forming an important additional aspect of the present disclosure. |